World Pharma News Digest - 10.09.2014
15 views
Skip to first unread message
Ruslan David
Sep 10, 2014, 7:03:23 AM9/10/14
to worldph...@googlegroups.com
GSK joins with research councils in UK and South Africa to tackle non-communicable diseases
GSK has announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK's Africa NCD Open Lab initiative.
Read more...
http://www.worldpharmanews.com/gsk/2884-gsk-joins-with-research-councils-in-uk-and-south-africa-to-tackle-non-communicable-diseases
Discovery paves the way for a new generation of chemotherapies
A new mechanism to inhibit proteasomes, protein complexes that are a target for cancer therapy, is the topic of an article published in the journal Chemistry & Biology. The first author of the study is Daniela Trivella, researcher at the Brazilian Biosciences National Laboratory at the Brazilian Center for Research in Energy and Materials (LNBio/CNPEM).
Read more...
http://www.worldpharmanews.com/research/2883-discovery-paves-the-way-for-a-new-generation-of-chemotherapies
Researchers improve severe asthma care through new, antibody-based treatment
A team of researchers at McMaster University and St. Joseph's Healthcare Hamilton have successfully evaluated a new, antibody-based drug for certain patients with severe asthma. The drug - named mepolizumab - can replace traditional, steroid-based treatments for a specific subset of patients, resulting in improved outcomes and reduced side effects.
Read more...
http://www.worldpharmanews.com/research/2882-researchers-improve-severe-asthma-care-through-new-antibody-based-treatment
Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies
Data presented at the European Respiratory Society (ERS) Congress today confirm the safety profile and the sustained efficacy of Adempas® (riociguat) over at least two years of treatment in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and in patients with pulmonary arterial hypertension (PAH).
Read more...
http://www.worldpharmanews.com/bayer/2881-safety-and-sustained-benefits-of-adempasr-from-bayer-confirmed-by-results-of-long-term-studies
Oxidized LDL might actually be 'good guy'
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions. Jason Meyer, a University of Kentucky MD-PhD candidate, worked with Deneys van der Westhuyzen, Ph.D., a Professor in the Departments of Internal Medicine and Molecular and Cellular Biochemistry, to study the role oxidized LDL plays in the development of plaque inside artery walls.
Read more...
http://www.worldpharmanews.com/research/2880-oxidized-ldl-might-actually-be-good-guy
Scientists discover how to 'switch off' autoimmune diseases
Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue. Rather than the body's immune system destroying its own tissue by mistake, researchers at the University of Bristol have discovered how cells convert from being aggressive to actually protecting against disease.
Read more...
http://www.worldpharmanews.com/research/2879-scientists-discover-how-to-switch-off-autoimmune-diseases
AstraZeneca and Redx Pharma agree research collaboration
AstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival. The research will complement AstraZeneca's strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.
Read more...
http://www.worldpharmanews.com/astrazeneca/2878-astrazeneca-and-redx-pharma-agree-research-collaboration
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
At the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done[1],[6].
Read more...
http://www.worldpharmanews.com/novartis/2877-novartis-new-heart-failure-medicine-lcz696-cut-cardiovascular-deaths-by-20-vs-ace-inhibitor-in-landmark-paradigm-hf-trial
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
AstraZeneca has announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.
Read more...
http://www.worldpharmanews.com/astrazeneca/2876-new-data-indicates-brilintabrilique-has-the-flexibility-to-be-initiated-pre-hospital-or-in-hospital-in-stemi-patients
Wine only protects against CVD in people who exercise
Wine only protects against cardiovascular disease (CVD) in people who exercise, according to results from the In Vino Veritas (IVV) study presented at ESC Congress by Professor Milos Taborsky from the Czech Republic. Professor Taborsky said: "This is the first randomised trial comparing the effects of red and white wine on markers of atherosclerosis (1) in people at mild to moderate risk of CVD.
Read more...
http://www.worldpharmanews.com/research/2875-wine-only-protects-against-cvd-in-people-who-exercise
A new synthetic amino acid for an emerging class of drugs
One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule. Ideally, the drug should have a shape that is perfectly complementary to a disease-causing target, so that it binds it with high specificity.
Read more...
http://www.worldpharmanews.com/research/2874-a-new-synthetic-amino-acid-for-an-emerging-class-of-drugs
Ebola vaccine trials fast-tracked by international consortium
A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in west Africa.
Read more...
http://www.worldpharmanews.com/gsk/2873-ebola-vaccine-trials-fast-tracked-by-international-consortium
NIH to launch human safety study of Ebola vaccine candidate
Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will evaluate the experimental vaccine's safety and ability to generate an immune system response in healthy adults.
Read more...
http://www.worldpharmanews.com/development/2872-nih-to-launch-human-safety-study-of-ebola-vaccine-candidate
PharmaNews.eu / Latest News
Eating is addictive but sugar and fat are not like drugs, study says
http://www.pharmanews.eu/research-and-development/1474-eating-is-addictive-but-sugar-and-fat-are-not-like-drugs-study-says
Scientists discover how to 'switch off' autoimmune diseases
http://www.pharmanews.eu/research-and-development/1473-scientists-discover-how-to-switch-off-autoimmune-diseases
Wine only protects against CVD in people who exercise
http://www.pharmanews.eu/research-and-development/1472-wine-only-protects-against-cvd-in-people-who-exercise
Fighting prostate cancer with a tomato-rich diet
http://www.pharmanews.eu/research-and-development/1471-fighting-prostate-cancer-with-a-tomato-rich-diet
A novel pathway for prevention of heart attack and stroke
http://www.pharmanews.eu/research-and-development/1470-a-novel-pathway-for-prevention-of-heart-attack-and-stroke
UCB expands access to clinical study data
http://www.pharmanews.eu/ucb/1469-ucb-expands-access-to-clinical-study-data
Europe to boost cooperation with international partners on generics
http://www.pharmanews.eu/ema/1468-europe-to-boost-cooperation-with-international-partners-on-generics
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
GSK has announced a £5m collaboration with the UK and South African Medical Research Councils, to support much-needed research into non-communicable diseases (NCDs) in Africa, as part of GSK's Africa NCD Open Lab initiative.
Read more...
http://www.worldpharmanews.com/gsk/2884-gsk-joins-with-research-councils-in-uk-and-south-africa-to-tackle-non-communicable-diseases
Discovery paves the way for a new generation of chemotherapies
A new mechanism to inhibit proteasomes, protein complexes that are a target for cancer therapy, is the topic of an article published in the journal Chemistry & Biology. The first author of the study is Daniela Trivella, researcher at the Brazilian Biosciences National Laboratory at the Brazilian Center for Research in Energy and Materials (LNBio/CNPEM).
Read more...
http://www.worldpharmanews.com/research/2883-discovery-paves-the-way-for-a-new-generation-of-chemotherapies
Researchers improve severe asthma care through new, antibody-based treatment
A team of researchers at McMaster University and St. Joseph's Healthcare Hamilton have successfully evaluated a new, antibody-based drug for certain patients with severe asthma. The drug - named mepolizumab - can replace traditional, steroid-based treatments for a specific subset of patients, resulting in improved outcomes and reduced side effects.
Read more...
http://www.worldpharmanews.com/research/2882-researchers-improve-severe-asthma-care-through-new-antibody-based-treatment
Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies
Data presented at the European Respiratory Society (ERS) Congress today confirm the safety profile and the sustained efficacy of Adempas® (riociguat) over at least two years of treatment in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment, and in patients with pulmonary arterial hypertension (PAH).
Read more...
http://www.worldpharmanews.com/bayer/2881-safety-and-sustained-benefits-of-adempasr-from-bayer-confirmed-by-results-of-long-term-studies
Oxidized LDL might actually be 'good guy'
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions. Jason Meyer, a University of Kentucky MD-PhD candidate, worked with Deneys van der Westhuyzen, Ph.D., a Professor in the Departments of Internal Medicine and Molecular and Cellular Biochemistry, to study the role oxidized LDL plays in the development of plaque inside artery walls.
Read more...
http://www.worldpharmanews.com/research/2880-oxidized-ldl-might-actually-be-good-guy
Scientists discover how to 'switch off' autoimmune diseases
Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue. Rather than the body's immune system destroying its own tissue by mistake, researchers at the University of Bristol have discovered how cells convert from being aggressive to actually protecting against disease.
Read more...
http://www.worldpharmanews.com/research/2879-scientists-discover-how-to-switch-off-autoimmune-diseases
AstraZeneca and Redx Pharma agree research collaboration
AstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival. The research will complement AstraZeneca's strategic approach focused on genetic drivers of cancer and mechanisms of resistance to established and novel cancer therapies.
Read more...
http://www.worldpharmanews.com/astrazeneca/2878-astrazeneca-and-redx-pharma-agree-research-collaboration
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
At the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done[1],[6].
Read more...
http://www.worldpharmanews.com/novartis/2877-novartis-new-heart-failure-medicine-lcz696-cut-cardiovascular-deaths-by-20-vs-ace-inhibitor-in-landmark-paradigm-hf-trial
New data indicates Brilinta/Brilique™ has the flexibility to be initiated pre-hospital or in hospital in STEMI patients
AstraZeneca has announced the results of the Phase IV ATLANTIC study, which indicates that the profile of BRILINTA/BRILIQUE™ (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients.
Read more...
http://www.worldpharmanews.com/astrazeneca/2876-new-data-indicates-brilintabrilique-has-the-flexibility-to-be-initiated-pre-hospital-or-in-hospital-in-stemi-patients
Wine only protects against CVD in people who exercise
Wine only protects against cardiovascular disease (CVD) in people who exercise, according to results from the In Vino Veritas (IVV) study presented at ESC Congress by Professor Milos Taborsky from the Czech Republic. Professor Taborsky said: "This is the first randomised trial comparing the effects of red and white wine on markers of atherosclerosis (1) in people at mild to moderate risk of CVD.
Read more...
http://www.worldpharmanews.com/research/2875-wine-only-protects-against-cvd-in-people-who-exercise
A new synthetic amino acid for an emerging class of drugs
One of the greatest challenges in modern medicine is developing drugs that are highly effective against a target, but with minimal toxicity and side-effects to the patient. Such properties are directly related to the 3D structure of the drug molecule. Ideally, the drug should have a shape that is perfectly complementary to a disease-causing target, so that it binds it with high specificity.
Read more...
http://www.worldpharmanews.com/research/2874-a-new-synthetic-amino-acid-for-an-emerging-class-of-drugs
Ebola vaccine trials fast-tracked by international consortium
A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in west Africa.
Read more...
http://www.worldpharmanews.com/gsk/2873-ebola-vaccine-trials-fast-tracked-by-international-consortium
NIH to launch human safety study of Ebola vaccine candidate
Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will evaluate the experimental vaccine's safety and ability to generate an immune system response in healthy adults.
Read more...
http://www.worldpharmanews.com/development/2872-nih-to-launch-human-safety-study-of-ebola-vaccine-candidate
PharmaNews.eu / Latest News
Eating is addictive but sugar and fat are not like drugs, study says
http://www.pharmanews.eu/research-and-development/1474-eating-is-addictive-but-sugar-and-fat-are-not-like-drugs-study-says
Scientists discover how to 'switch off' autoimmune diseases
http://www.pharmanews.eu/research-and-development/1473-scientists-discover-how-to-switch-off-autoimmune-diseases
Wine only protects against CVD in people who exercise
http://www.pharmanews.eu/research-and-development/1472-wine-only-protects-against-cvd-in-people-who-exercise
Fighting prostate cancer with a tomato-rich diet
http://www.pharmanews.eu/research-and-development/1471-fighting-prostate-cancer-with-a-tomato-rich-diet
A novel pathway for prevention of heart attack and stroke
http://www.pharmanews.eu/research-and-development/1470-a-novel-pathway-for-prevention-of-heart-attack-and-stroke
UCB expands access to clinical study data
http://www.pharmanews.eu/ucb/1469-ucb-expands-access-to-clinical-study-data
Europe to boost cooperation with international partners on generics
http://www.pharmanews.eu/ema/1468-europe-to-boost-cooperation-with-international-partners-on-generics
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
Health IT Space, http://www.healthitspace.eu
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages